This is the fifth survey assessing the capacity and needs of laboratories in the EU/EEA, with a focus on antigenic characterisation capability and capacity for SARS-CoV-2 viruses.
ECDC has worked with EU/EEA countries to develop a methodology for regular national reporting of existing national surveillance data on COVID-19 in LTCFs, aiming for maximum feasibility. This is to enable ECDC to communicate timely information on epidemiological trends of COVID-19 in LTCFs, in support of national and EU/EEA-level preparedness and response activities.
ECDC has awarded more than 77 M€ to 24 EU/EEA countries to strengthen whole genome sequencing and RT-PCR infrastructures within the countries’ national public health programmes.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
ECDC and the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) have launched a number of activities to help strengthen EU/EEA Member States’ capacity for detection of SARS-CoV-2 variants in the shorter and longer term. These activities are one of five action areas of the ‘HERA Incubator’, a new EU bio-defence preparedness plan against SARS-CoV-2 variants launched by the European Commission on 17 February 2021.
This document offers practical guidance for EU/EEA Member States on implementing genomic SARS-CoV-2 surveillance. It also includes advice on how to estimate the number of sequenced samples needed to achieve various objectives, including the early detection of novel variants.
Several SARS-CoV-2 variants have been identified. Some of these variants have mutations that (alone or in combination) may provide the virus with a selective advantage, such as increased transmissibility or the ability to evade the host immune response, or cause possible changes in pathogenicity, thus increasing disease severity.
This document outlines the use of saliva as a diagnostic sample for detecting SARS-CoV-2 infection, considering the advantages, limitations and uncertainties associated with the use of saliva as sample material.